Effect of misoprostol on postprandial intestinal motility and orocecal transit time in humans
- PMID: 8482184
- DOI: 10.1007/BF01295911
Effect of misoprostol on postprandial intestinal motility and orocecal transit time in humans
Abstract
We measured the effect of misoprostol (M), a PGE1 analog, on duodenojejunal postprandial motor activity and orocecal transit in eight healthy volunteers. Intestinal motility was studied by an intraluminal catheter with three strain gauge transducers connected to a solid-state datalogger, and transit time was measured by a hydrogen breath test. Subjects were studied for two consecutive days and fed twice a day with a similar, 600-kcal meal. Misoprostol (M) at 800, 400, or 200 micrograms or placebo were taken orally before every one of the four meals. Transit time was measured after the morning meal on both days, after ingestion of either 800 micrograms of M or placebo. On four occasions, following M, the normal fed pattern was not established and the migrating motor complex (MMC) was not interrupted by the meal. In all other occasions, when the higher doses of M were given, the first 1-2 hr after the meal revealed a hypoactive bowel. This effect was inconsistently seen following 200 micrograms of M. Orocecal transit time was consistently and significantly shorter after M than placebo: 48.3 +/- 9.5 min vs 104.4 +/- 4.8 min, P < 0.0001. Four subjects had diarrhea during the study. We conclude that misoprostol, particularly at higher doses, has a profound effect on intestinal postprandial motility and results in accelerated transit time. The motility changes induced by M may be responsible, in part, for its effect on transit.
Similar articles
-
Effect of exercise on intestinal motility and transit in trained athletes.Am J Physiol. 1991 May;260(5 Pt 1):G698-702. doi: 10.1152/ajpgi.1991.260.5.G698. Am J Physiol. 1991. PMID: 2035639
-
Effects on bowel motility of misoprostol administered before and after meals.Aliment Pharmacol Ther. 1991 Oct;5(5):533-42. doi: 10.1111/j.1365-2036.1991.tb00522.x. Aliment Pharmacol Ther. 1991. PMID: 1793784 Clinical Trial.
-
Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers.Clin Ther. 2006 Apr;28(4):569-81. doi: 10.1016/j.clinthera.2006.04.003. Clin Ther. 2006. PMID: 16750468 Clinical Trial.
-
Endogenous nitric oxide modulates small intestinal nutrient transit and activity in healthy adult humans.Scand J Gastroenterol. 2005 Nov;40(11):1290-5. doi: 10.1080/00365520510023710. Scand J Gastroenterol. 2005. PMID: 16334438 Clinical Trial.
-
Neurohormonal control of intestinal transit.Reprod Nutr Dev. 1994;34(6):513-25. doi: 10.1051/rnd:19940601. Reprod Nutr Dev. 1994. PMID: 7840868 Review.
Cited by
-
Misoprostol is effective treatment for patients with severe chronic constipation.Dig Dis Sci. 1994 May;39(5):929-33. doi: 10.1007/BF02087539. Dig Dis Sci. 1994. PMID: 8174433 Clinical Trial.
-
Chronic effects of misoprostol in combination with the NSAID, diclofenac, on gastrointestinal tract of pigs. Relation to diarrheagenic activity, leukocyte infiltration, and mucosal leukotrienes.Dig Dis Sci. 1995 Jul;40(7):1435-44. doi: 10.1007/BF02285189. Dig Dis Sci. 1995. PMID: 7628265
-
Chronic Intestinal Pseudo-obstruction.Curr Treat Options Gastroenterol. 1999 Jun;2(3):239-250. doi: 10.1007/s11938-999-0063-9. Curr Treat Options Gastroenterol. 1999. PMID: 11097724
-
Exploring Pharmacological Treatments for Chronic Idiopathic Constipation in Adults: A Look Back to the Future.J Clin Med. 2023 Feb 20;12(4):1702. doi: 10.3390/jcm12041702. J Clin Med. 2023. PMID: 36836237 Free PMC article. Review.
-
Current and Emerging Medical Therapies for Gastroparesis.Curr Treat Options Gastroenterol. 2015 Dec;13(4):452-72. doi: 10.1007/s11938-015-0071-x. Curr Treat Options Gastroenterol. 2015. PMID: 26507073